Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALEC

ALEC - Alector Inc Stock Price, Fair Value and News

6.47USD+0.26 (+4.19%)Market Closed
Watchlist

Market Summary

USD6.47+0.26
Market Closed
4.19%

ALEC Stock Price

View Fullscreen

ALEC RSI Chart

ALEC Valuation

Market Cap

544.4M

Price/Earnings (Trailing)

-3.85

Price/Sales (Trailing)

5.65

Price/Free Cashflow

-2.87

ALEC Price/Sales (Trailing)

ALEC Profitability

Return on Equity

-86.98%

Return on Assets

-21.03%

Free Cashflow Yield

-34.89%

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

96.3M

Rev. Growth (Yr)

-38.67%

Rev. Growth (Qtr)

-83.8%

ALEC Earnings

Earnings (TTM)

-141.4M

Earnings Growth (Yr)

3.63%

Earnings Growth (Qtr)

-3.3K%

Breaking Down ALEC Revenue

Last 7 days

-1.2%

Last 30 days

-18.1%

Last 90 days

47.8%

Trailing 12 Months

-32.4%

How does ALEC drawdown profile look like?

ALEC Financial Health

Current Ratio

3.95

ALEC Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

-1.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023125.7M102.1M96.3M0
2022227.4M300.7M133.2M133.6M
202118.0M21.4M197.9M207.1M
202022.8M19.0M22.2M21.1M
201928.4M28.2M24.4M21.2M
20188.4M15.2M21.6M27.7M
20171.2M2.1M2.9M3.7M
2016000416.0K

Tracking the Latest Insider Buys and Sells of Alector Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 05, 2023
garofalo elizabeth a.
gifted
-
-
-9,459
-
Dec 04, 2023
rosenthal arnon
sold
-132,500
5.56
-23,831
chief executive officer
Dec 04, 2023
grasso marc
sold
-25,431
5.56
-4,574
chief financial officer
Dec 04, 2023
kenkare-mitra sara
sold
-69,605
5.56
-12,519
president and head of r&d
Dec 04, 2023
romano gary
sold
-27,994
5.56
-5,035
chief medical officer
Oct 01, 2023
grasso marc
acquired
-
-
123,000
chief financial officer
Oct 01, 2023
romano gary
acquired
-
-
108,000
chief medical officer
Oct 01, 2023
kenkare-mitra sara
acquired
-
-
163,600
president and head of r&d
Oct 01, 2023
rosenthal arnon
acquired
-
-
397,600
chief executive officer
Sep 11, 2023
mcguire terrance
sold
-3,000,000
6.00
-500,000
-

1–10 of 50

Which funds bought or sold ALEC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
4.76
2,157,000
9,590,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
16.00
16.00
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-9.8
9,208
92,353
0.06%
Feb 15, 2024
Legal & General Group Plc
reduced
-0.28
88,366
475,942
-%
Feb 15, 2024
BARCLAYS PLC
added
39.19
643,000
1,542,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
69.87
439,124
841,292
-%
Feb 15, 2024
MEDICI CAPITAL LLC
added
223
1,151,560
1,538,120
1.78%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
added
1.05
616,218
3,136,940
0.01%
Feb 14, 2024
BAKER BROS. ADVISORS LP
sold off
-100
-6,252,230
-
-%
Feb 14, 2024
AMUNDI
reduced
-56.37
-105,743
150,595
-%

1–10 of 46

Are Funds Buying or Selling ALEC?

Are funds buying ALEC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALEC
No. of Funds

Unveiling Alector Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.21%
4,386,541
SC 13G/A
Feb 12, 2024
morgan stanley
5.5%
4,605,044
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
polaris venture partners vi, l.p.
0.5%
498,468
SC 13G/A
Feb 08, 2024
rosenthal arnon
-
7,285,773
SC 13G
Jan 24, 2024
blackrock inc.
9.6%
8,068,553
SC 13G/A
Oct 13, 2023
fmr llc
-
0
SC 13G/A
Oct 10, 2023
fil ltd
-
0
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
4.9%
4,056,548
SC 13G/A
Feb 10, 2023
rosenthal arnon
-
6,884,362
SC 13G/A

Recent SEC filings of Alector Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
SC 13G
Major Ownership Report
Jan 24, 2024
SC 13G/A
Major Ownership Report
Jan 19, 2024
424B5
Prospectus Filed
Jan 19, 2024
8-K
Current Report
Jan 16, 2024
424B5
Prospectus Filed

What is the Fair Value of ALEC?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Alector Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Alector Inc News

Latest updates
AmericanBankingNEWS5 hours ago
InvestorsObserver07 Feb 202404:39 pm
Seeking Alpha07 Feb 202408:00 am
InvestorsObserver26 Dec 202308:00 am
Simply Wall St2 months ago

Alector Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-83.8%9.0056.0017.0014.0015.0080.0024.0014.001827.004.005.006.003.007.006.003.007.006.009.007.00
Operating Expenses-0.2%60.0060.0067.0070.0063.0070.0069.0070.0056.0062.0057.0058.0060.0050.0049.0038.0037.0034.0026.0028.0023.00
  S&GA Expenses-1.9%13.0014.0015.0015.0014.0016.0016.0017.0013.0014.0011.0013.0016.0016.0015.0013.008.008.006.004.003.00
  R&D Expenses0.3%46.0046.0052.0054.0048.0055.0053.0053.0043.0048.0046.0044.0044.0034.0035.0026.0029.0026.0021.0024.0020.00
Income Taxes-10.1%1.001.001.001.001.001.001.00--------------
Net Income-3334.5%-44.471.00-45.86-52.43-46.1510.00-44.62-55.61127-55.15-52.17-52.18-52.70-45.33-40.02-30.53-31.74-24.56-18.56-17.37-15.32
Net Income Margin-4.7%-1.47*-1.40*-1.07*-1.00*-1.02*0.12*-0.13*-0.18*-0.17*-9.90*-11.22*-9.02*---------
Free Cashflow-5.0%-46.45-44.22-49.57-49.69-50.97-58.19134-49.82444-45.37-53.64-48.45---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.1%672709748788837890954815854397440488532572619422450477496308290
  Current Assets-5.4%613648686726775827891750788329375422470510556357385415442293-
    Cash Equivalents-22.5%10213219615418417245533151712611150.0085.0093.0016191.0087.0069.0061.0067.0042.00
  Net PPE-4.8%23.0024.0025.0026.0026.0026.0026.0027.0028.0029.0029.0030.0031.0032.0033.0034.0034.0032.0022.0011.00-
Liabilities-0.5%510512565573584601687514518213213221221217227227231232230195199
  Current Liabilities17.5%15513299.0094.0016114914314013374.0064.0068.0071.0066.0072.0062.0059.0067.0056.0048.00-
Shareholder's Equity-17.2%16319618321425328926830133618522826831035539219521924626617.0014.00
  Retained Earnings-7.1%-668-624-625-579-527-481-490-446-390-517-462-410-357-305-259-219-189-157-132-114-
  Additional Paid-In Capital1.2%83282281179978777676274872770269067766765964941440840339917.00-
Shares Outstanding0.4%84.0084.0083.0083.0083.0082.0082.0082.0081.0080.0079.0078.00---------
Float------627---1,193---1,376---549---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-8.2%-46,540-43,004-48,548-48,925-49,053-57,442135,091-49,265445,052-44,543-52,693-47,658-40,821-45,942-32,313-28,827-28,863-18,052-23,566-17,654-22,359
  Share Based Compensation-1.6%10,05910,22210,97510,96310,76612,47811,93912,70610,2019,0788,8008,9028,0306,9486,6425,2384,1043,6943,2452,6601,980
Cashflow From Investing177.7%16,961-21,81588,70118,38160,530-225,819-12,106-146,753-69,05456,591109,55311,55233,013-24,744-124,87230,05745,90926,422-151,26242,465-46,946
Cashflow From Financing-100.0%-8811,0796364899062,4838,63814,8212,9623,8741,0962862,270228,4611,437720-116170,312-1,28062,334

ALEC Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue$ 9,109$ 14,852$ 81,872$ 119,177
Operating expenses:    
Research and development46,32848,348144,392155,925
General and administrative13,36414,25241,76745,648
Total operating expenses59,69262,600186,159201,573
Loss from operations(50,583)(47,748)(104,287)(82,396)
Other income, net7,3602,33318,8764,047
Loss before income taxes(43,223)(45,415)(85,411)(78,349)
Income tax expense1,2527333,5462,533
Net loss(44,475)(46,148)(88,957)(80,882)
Unrealized gain (loss) on marketable securities665(518)3,854(5,799)
Comprehensive loss$ (43,810)$ (46,666)$ (85,103)$ (86,681)
Net loss per share, basic$ (0.53)$ (0.56)$ (1.07)$ (0.98)
Net loss per share, diluted$ (0.53)$ (0.56)$ (1.07)$ (0.98)
Shares used in computing net loss per share, basic83,927,96182,602,84283,513,95482,367,936
Shares used in computing net loss per share, diluted83,927,96182,602,84283,513,95482,367,936

ALEC Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 101,964$ 154,323
Marketable securities486,897558,528
Receivable from Collaboration partner10,4652,587
Prepaid expenses and other current assets13,82110,997
Total current assets613,147726,435
Property and equipment, net23,11525,521
Operating lease right-of-use assets26,03927,811
Restricted cash1,5461,472
Other assets8,5486,409
Total assets672,395787,648
Current liabilities:  
Accounts payable4,6794,189
Accrued clinical supply costs7,4305,559
Accrued liabilities30,42327,771
Deferred revenue, current portion80,56148,231
Refund liability to collaboration partner, current portion23,9190
Operating lease liabilities, current portion8,3908,059
Total current liabilities155,40293,809
Deferred revenue, long-term portion229,848443,370
Refund liability to collaboration partner, long-term portion91,8490
Operating lease liabilities, long-term portion31,84335,268
Other long-term liabilities898759
Total liabilities509,840573,206
Commitments and contingencies (Note 4)
Stockholders' equity:  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,136,381 and 82,895,718 shares issued and outstanding as of September 30, 2023 and December 31, 202288
Additional paid-in capital831,912798,696
Accumulated other comprehensive loss(721)(4,575)
Accumulated deficit(668,644)(579,687)
Total stockholders' equity162,555214,442
Total liabilities and stockholders’ equity$ 672,395$ 787,648
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.alector.com
 EMPLOYEES239

Alector Inc Frequently Asked Questions


What is the ticker symbol for Alector Inc? What does ALEC stand for in stocks?

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alector Inc (ALEC)?

As of Thu Feb 22 2024, market cap of Alector Inc is 544.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers. The fair value of Alector Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alector Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALEC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alector Inc a good stock to buy?

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

What is Alector Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ALEC's PE ratio (Price to Earnings) is -3.85 and Price to Sales (PS) ratio is 5.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.